PURPOSE
VIOLETTE (NCT03330847) assessed olaparib alone or with ceralasertib (ATR inhibitor) or adavosertib (WEE1 inhibitor) as second-/third-line treatment in three molecular strata of patients with previously treated, PARP inhibitor-naïve, advanced triple-negative breast cancer (TNBC).
PATIENTS AND METHODS
Patients...
A. Tutt, Z. Nowecki, R. Szoszkiewicz et al.· Clinical Cancer Research· 0 citations
PURPOSE
Talazoparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. Although PARP inhibitor sensitivity has traditionally been attributed to synthetic letha...
Miso Lee, Kyung-Hun Lee, Ahrum Min et al.· Journal of Breast Cancer· 0 citations
BACKGROUND
Ceralasertib, an ATR inhibitor, is known to exacerbate replication stress induced by the PARP inhibitor (PARPi) olaparib, with the combination having the potential to overcome PARPi resistance in the clinic. This modular Phase 1 study evaluated the combination in advanced solid tumours, including breast canc...
J. Lopez, Seock-Ah Im, S. Postel-Vinay et al.· British Journal of Cancer· 0 citations
AIMS
To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications.
METHODS AND RESULTS
A total of 203 patients with TNBC treated...
Jiwon Koh, K. J. Suh, H. Park et al.· Histopathology· 0 citations
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies. A multitarget gene therapy was developed and validated to overcome molecular heterogeneity and compensatory survival signaling in TNBC. A codon-optimized human transcriptional intermediary factor 1 gamma (opti-hTIF1γ) ge...
Hyomin Park, Tae Yoon Kim, Hyun-Jeung Yun et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.